ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 2888 • 2018 ACR/ARHP Annual Meeting

    Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis

    Borja Hernández-Breijo1, Victoria Navarro-Compán1, Ana Martínez1, Andrea Jochems1, Alejandro Villalba2, Diana Peiteado3, Eva L. Kneepkens4, Gerrit Wolbink4, Theo Rispens5, Dora Pascual-Salcedo1, Alejandro Balsa1 and Chamaida Plasencia1, 1Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, 2Rheumatology, La Paz University Hospital, Madrid, Spain, 3Hospital Universitario La Paz, Madrid, Spain, 4Rheumatology, Reade, Amsterdam, Netherlands, 5Immunopathology, Sanquin Research, Amsterdam, Netherlands

    Background/Purpose: In patients with axial spondyloarthritis (axSpA), the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate (MTX) and sulfasalazine (SSZ), as well…
  • Abstract Number: 1936 • 2018 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

    Piotr Wiland1, Sławomir Jeka2, Eva Dokoupilová3,4, Juan Manuel Miranda Limón5, Julia Jauch-Lembach6, Anjali Thakur6, Halimuniyazi Haliduola6 and Norman B Gaylis7, 1Wrocław Medical University, Wrocław, Poland, 2Collegium Medicum UMK, 2nd University Hospital, Bydgoszcz, Poland, 3MEDICAL PLUS s.r.o., Uherské Hradiště, Czech Republic, 4Faculty of Pharmacy, University of Veterinary and Pharmaceutical sciences, Brno, Czech Republic, 5RM Pharma Specialists, Mexico City, Mexico, 6Hexal AG, Holzkirchen, Germany, 7Arthritis & Rheumatic Disease Specialties, Aventura, FL

    Background/Purpose: GP2017, a proposed adalimumab biosimilar, matched reference adalimumab (refADL) in preclinical and pharmacokinetics studies.1,2 The confirmatory efficacy and safety study in patients with plaque-type…
  • Abstract Number: 2890 • 2018 ACR/ARHP Annual Meeting

    Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study

    Jun Won Park1, Min Jung Kim1, Hyoun-Ah Kim2, Kichul Shin3, Yong-Beom Park4, Yeong Wook Song5 and Eun Young Lee1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 2Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), 3Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), 4Yonsei University College of Medicine, Seoul, Korea, Republic of (South), 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)

    Background/Purpose: Although recent treatment guideline of axial spondyloarthritis (axSpA) by the European League Against Rheumatism (EULAR) recommended that tapering of tumor necrosis factor inhibitor (TNFi)…
  • Abstract Number: 2270 • 2018 ACR/ARHP Annual Meeting

    Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo1, Vanesa Calvo-Río2, Monica Calderón Goercke2, Diana Prieto Peña2, Rosalía Demetrio-Pablo3, Javier Loricera3, Eva Peña Sainz-Pardo3, M. Victoria Hernández4, Alfredo Adan5, Marina Mesquida5, Santos Insua6, Jose M Herreras7, Olga Maíz8, Ana Blanco9, Myriam Gandía10, David Diaz-Valle11, Lucía Martínez-Costa12, Elia Valls-Pascual12, Gisela Díaz-Cordovés13, Manuel Díaz-Llopis14, Inmaculada Calvo15, Ignacio Torre-Salaberri16, Antonio Atanes17, Luis Francisco Linares18, Marisa Hernández19, Emma Beltrán20, Miguel Cordero-Coma21, Elena Aurrecoechea22, Félix Francisco23, Raquel Almodóvar González24, Oscar Ruiz Moreno25, Fernando Jiménez-Zorzo26, Joan Miquel Nolla27, Consuelo Modesto28, Enar Pons1, Miguel Angel González-Gay3 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 7Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 8Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 9Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 10Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 11Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 12Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 13Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, 14Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 15Hospital Universitario La Fe, Valencia, Spain, 16Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 17Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 18Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 19Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 20Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 21Ophthalmology, Hospital de León. Spain, León, Spain, 22Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, 23Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 24Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 25Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 26Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 27Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 28Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain

    Background/Purpose: Cystoid macular edema (CME) is the main cause of irreversible visual loss in patients with uveitis. Our aim objective was to determine the efficacy…
  • Abstract Number: 546 • 2017 ACR/ARHP Annual Meeting

    Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis

    Ming Zhao1, Harlan Sayles2, James R. O'Dell1 and Kaleb Michaud2,3, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3National Data Bank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) have been widely used in patients who failed conventional DMARDs in the treatment of rheumatoid arthritis (RA). While most…
  • Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting

    Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis

    Gareth T. Jones1, Andrew Keat2, Ejaz Pathan3 and Gary J. Macfarlane1, 1Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, 2Rheumatology., Northwick Park Hospital, London, United Kingdom, 3Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom

    Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…
  • Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting

    Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations

    Shalini Mohan1, Margaret Michalska2, Jeffrey Yourish2, Jinglan Pei2, Sara Gale1, Christine Birchwood2 and Erhan Berber2, 1Genentech, South San Francisco, CA, 2Genentech, Inc., South San Francisco, CA

    Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…
  • Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting

    Opioid Use in Patients with Ankylosing Spondylitis

    Victor S. Sloan1, Anna Sheahan1, Jeffrey Stark2 and Robert Y. Suruki1, 1UCB Pharma, Raleigh, NC, 2UCB Pharma, Smyrna, GA

    Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…
  • Abstract Number: 606 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses

    Philip J Mease1, Iain B. McInnes2, Kristian Reich3, Peter Nash4, Mats Andersson5, Ken Abrams6, Luminita Pricop6 and Todd Fox5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2University of Glasgow, Glasgow, United Kingdom, 3Dermatologikum Hamburg, Hamburg, Germany, 4University of Queensland, Brisbane, Australia, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.1, 2…
  • Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting

    Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J Mease1, Chitra Karki2, Mei Liu2, YouFu Li3, Peter Hur4 and Jeffrey D. Greenberg5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5New York University School of Medicine, New York, NY

    Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…
  • Abstract Number: 630 • 2017 ACR/ARHP Annual Meeting

    Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial

    M. Elaine Husni1, Arthur Kavanaugh2, Eric K. H. Chan3, Nan Li4, Steven Peterson4, Elizabeth C. Hsia5, Lilianne Kim4, Kim Hung Lo4 and Diane D. Harrison4, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Medicine, University of California, San Diego, La Jolla, CA, 3Janssen Global Services, LLC, Raritan, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA

    Background/Purpose: To evaluate physical and mental health functioning, health state, and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA) treated with…
  • Abstract Number: 1570 • 2017 ACR/ARHP Annual Meeting

    Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio

    Valéria F. Caparbo1, Carla G.S. Saad1, Julio C. B. Moraes2, Artur J de Brum-Fernandes3 and Rosa M R Pereira4, 1Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division, Université de Sherbrooke, Rheumatology Division, Canada, Sherbrooke, QC, Canada, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease characterized by new bone growth that leads to syndesmophyte formation and subsequent vertebral ankyloses, although AS…
  • Abstract Number: 638 • 2017 ACR/ARHP Annual Meeting

    Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?

    Pierluigi Macchioni1, Giovanni Ciancio2, Gilda Sandri3, Alen Zabotti4, Luca Montaguti5, Gentiana Vukatana6, Fabio Mascella7, Donatella Chessa8, Elisa Verduci9, Marcello Govoni10, Amelia Spinella3, Francesca Zuliani11, Marco Bruschi5, Nazzarena Malavolta12 and Mariacristina Focherini7, 1Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, 3Rheumatology Unit, University fo Modena & Reggio, Modena, Italy, 4Rheumatology Clinic, Department of Medical and Biological Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, 5Dipartimento Internistico SS di Reumatologia, AUSL Romagna Ospedale Bufalini, Cesena, Italy, 6Rheumatology Unit, Department CardioThoracic Vascular, S.Orsola- Malpighi Hospital, Alma Mater Studiorum, Bologna, Bologna, Italy, 7Internal Medicine and Rheumatology, Ospedale Infermi Rimini, Rimini, Italy, 8Internal Medicine, Ospedale Paolo Dettori, Tempio Pausania, Italy, 9Rheumatology Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy, 10Rheumatology Clinic, Department of Medical and Biological Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria Sant’Anna - Ferrara (Italy), ferrara, Italy, 11Rheumatology Unit, Department of Medical Sciences, Santa Maria della Misericordia" University Hospital, Udine, Italy, 12Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy

    Background/Purpose: Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with psoriatic arthritis (PA) in clinical remission. To evaluate if there are clinical, demographic…
  • Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting

    Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis

    Michaela Koehm1, Michael Hofmann2, Rasmus Lüthje2, Matthew McIntosh3, Varghese Abraham3, Cem Gabay4, Arthur Kavanaugh5, Harald Burkhardt6 and Frank Behrens6, 1Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, 2Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, 3Genentech, San Francisco, CA, 4SCQM, Geneva, Switzerland, Geneva, Switzerland, 5Medicine, University of California, San Diego, La Jolla, CA, 6Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

    Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
  • Abstract Number: 1019 • 2017 ACR/ARHP Annual Meeting

    Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment

    Victor Farutin1, Thomas Prod'homme1, Kevin McConnell1, Nathaniel Washburn1, Patrick Halvey1, Jamey Guess1, Nur Sibel Gunay1, Jan Hillson2, Carol J. Etzel3, Katherine C. Saunders3, Dimitrios A. Pappas3,4, Anthony Manning1, Leona Ling1 and Ishan Capila1, 1Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, 2Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, 3Corrona, LLC, Southborough, MA, 4Columbia University, New York, NY

    Background/Purpose: Despite the success of anti-TNF therapies in RA, ~ 30 % of patients are non-responders. Several studies have focused on understanding the biology underlying…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology